Print Page    E-mail Page    RSS    E-mail Alerts 


Corporate Profile

At Bellerophon Therapeutics, we aim to transform the lives of people suffering from cardiopulmonary and cardiac diseases by developing innovative therapies at the intersection of drugs and devices for these therapeutic areas and to do so while serving the best interests of our shareholders.

more >
Stock Quotemore >
 Stock is Up 0.20 (16.67%)
Bellerophon (Nasdaq: BLPH)
Data as of 02/24/17 4:00 p.m. ET
Minimum 20 minute delay
Recent Newsmore >
Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
Protocol Changes have Potential to Reduce Time to Market for INOpulse by Approximately Two Years and Will Result in Substantial Cost Savings for Company WARREN, N.J., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced that it received confirmation from the U.S. Food and Drug Administration (FDA) of the Agency’s acceptance of all modifications proposed by the Company to its Phase 3 program for INOpulse in Pu... 
Bellerophon Therapeutics, Inc. Announces $12 Million Public Offering
WARREN, N.J., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today announced the pricing of a public offering with expected total gross proceeds of approximately $12 million. The offering is expected to close on or about November 29, 2016, subject to satisfaction of customary closing conditions. The offering was priced at $0.70 per Class A Unit (consisting of one share of our common stock and a warrant to purchase on... 
Bellerophon Reports Third Quarter 2016 Financial Results and Provides Business Update
WARREN, N.J., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today reported financial results for the third quarter ended September 30, 2016 and provided a business update. “Overall, I am pleased to report good progress in our ongoing Phase 3 clinical trial to treat Pulmonary Arterial Hypertension (PAH), under an FDA-granted Special Protocol Assessment,” stated Jonathan Peacock, Chairman and Chief Executive Officer o... 
Upcoming Eventsmore >
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources